Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Indaptus Therapeutics Logo
Indaptus Therapeutics Growth Score
52
CB Rank
33795
Heat Score
62
Indaptus Therapeutics develops a platform that activates both innate and adaptive cellular anti-tumor pathways.
Founded
obfuscation
PublicPost-IPO Equity New York, New York, United States1-10 indaptusrx.com/
Health Care
Medical
Medical Device
Overview

Indaptus Therapeutics
Total Funding
obfuscation
Growth Score
52
Heat Score
62

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score52
-10 pts
in past quarter
Heat Score 62
-4 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
See more interactive data and historical milestones on desktop for the best experience

About Indaptus Therapeutics

CB Rank
33795
Indaptus Therapeutics develops a platform that activates both innate and adaptive cellular anti-tumor pathways.
Founded
obfuscation
PublicPost-IPO Equity New York, New York, United States1-10 indaptusrx.com/
Health Care
Medical
Medical Device

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Debt
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name Indaptus Therapeutics, Inc.
Operating Status Active
Stock Symbol  NASDAQ:INDP
Company Type For Profit
Founders  Michael Newman
About the Company
Indaptus Therapeutics focuses on revolutionizing the treatment of cancer and certain infectious diseases. Its proprietary platform exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways.
Predictions & Insights

Growth Insight

See this Growth Insight
Indaptus Therapeutics is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

Decoy20
An intravenous immunotherapy candidate using attenuated, killed non-pathogenic gram-negative bacteria to activate innate and adaptive immune responses against advanced solid tumors.
Decoy10 (INDP010)
A chemically modified bacterial platform strain designed to activate immune responses for multiple indications including cancer and infectious diseases.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 6
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Indaptus Therapeutics Logo
Post-IPO Equity - Indaptus Therapeutics
1
obfuscation
David LazarPost-IPO Equity
obfuscation
Post-IPO Equity - Indaptus Therapeutics Logo
Post-IPO Equity - Indaptus Therapeutics
1
obfuscation
David LazarPost-IPO Equity
obfuscation
Post-IPO Equity - Indaptus Therapeutics Logo
Post-IPO Equity - Indaptus Therapeutics
1
obfuscation
David LazarPost-IPO Equity
obfuscation
Post-IPO Equity - Indaptus Therapeutics Logo
Post-IPO Equity - Indaptus Therapeutics
1
obfuscation
David LazarPost-IPO Equity
obfuscation
Post-IPO Equity - Indaptus Therapeutics Logo
Post-IPO Equity - Indaptus Therapeutics
1
obfuscation
David LazarPost-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 6
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Indaptus Therapeutics Logo
Post-IPO Equity - Indaptus Therapeutics
1
obfuscation
David LazarPost-IPO Equity
obfuscation
Post-IPO Equity - Indaptus Therapeutics Logo
Post-IPO Equity - Indaptus Therapeutics
1
obfuscation
David LazarPost-IPO Equity
obfuscation
Post-IPO Equity - Indaptus Therapeutics Logo
Post-IPO Equity - Indaptus Therapeutics
1
obfuscation
David LazarPost-IPO Equity
obfuscation
Post-IPO Equity - Indaptus Therapeutics Logo
Post-IPO Equity - Indaptus Therapeutics
1
obfuscation
David LazarPost-IPO Equity
obfuscation
Post-IPO Equity - Indaptus Therapeutics Logo
Post-IPO Equity - Indaptus Therapeutics
1
obfuscation
David LazarPost-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
David Lazar Logo
David Lazar
Yes
Post-IPO Equity - Indaptus Therapeutics Logo
Post-IPO Equity - Indaptus Therapeutics
—
David Lazar Logo
David Lazar
Yes
Post-IPO Equity - Indaptus Therapeutics Logo
Post-IPO Equity - Indaptus Therapeutics
—
David Lazar Logo
David Lazar
Yes
Post-IPO Equity - Indaptus Therapeutics Logo
Post-IPO Equity - Indaptus Therapeutics
—
David Lazar Logo
David Lazar
Yes
Post-IPO Equity - Indaptus Therapeutics Logo
Post-IPO Equity - Indaptus Therapeutics
—
David Lazar Logo
David Lazar
Yes
Post-IPO Equity - Indaptus Therapeutics Logo
Post-IPO Equity - Indaptus Therapeutics
—

Investments

Number of Acquisitions 2

Investment Breakdown

Number of Acquisitions 2
Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Employee Profiles 4 Board Members and Advisors 1 Contacts 5

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jun 2, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 4, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Dec 29, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Dec 29, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

69
-88.16%
 in past month

IT Spend

$114.2KThis year, Indaptus Therapeutics is projected to spend $114.2K on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Business Insider Logo
Business Insider
74
Newsweek Logo
Newsweek
66
Forbes Logo
Forbes
65

Actively Used Products

10Indaptus Therapeutics uses 10 technology products and services including HTML5, Vimeo, and  Google Analytics, according to G2 Stack.

Active Website Tech Count

3Indaptus Therapeutics is actively using 3 technologies for its website, according to BuiltWith. These include CommonCrawl Top 50m and  Euro.

Total IP

9The intellectual property of Indaptus Therapeutics includes 9 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery.
Sub-Organizations

Sub-Organizations

Number of Sub-Orgs 1
Which industries do these Sub-Organization operate in?
Intec Pharma Logo
Intec PharmaSubsidiary
Frequently Asked Questions

Where is Indaptus Therapeutics's headquarters? Indaptus Therapeutics is located in New York, New York, United States.Who invested in Indaptus Therapeutics? Indaptus Therapeutics is funded by David Lazar.When was the last funding round for Indaptus Therapeutics? Indaptus Therapeutics closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Indaptus Therapeutics's competitors? Alternatives and possible competitors to Indaptus Therapeutics may include Canton Strategic Holdings, Monte Rosa Therapeutics, and  Centauri Therapeutics.How much funding has Indaptus Therapeutics raised to date? Indaptus Therapeutics has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(5eb04bf 1)
|